Navigation Links
Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
Date:11/12/2009

PLEASANTON, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will webcast its investor event to discuss data from the HeartMate II Destination Therapy clinical trial that will be presented during the late-breaking clinical trial session at the American Heart Association(AHA) Scientific Sessions 2009.

The event will begin at 1:30 p.m., Eastern Standard Time (10:30 a.m., Pacific Standard Time), on Tuesday, November 17. The event will be available through the company's website at www.thoratec.com. It will also be archived on the company's website.

The event will include a review of the trial data by Dr. Joseph Rogers of Duke University, who is presenting the data at AHA as a late-breaking clinical trial, and comments from Gary F. Burbach, president and chief executive officer of Thoratec.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System), with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's websites at http://www.thoratec.com or http://www.itcmed.com.

SOURCE Thoratec Corporation


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Presentation at Canaccord Adams Conference to be Webcast
5. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
8. BD to Present at Investor Healthcare Conferences
9. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
10. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
11. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... Jan. 20, 2017 ARMO BioSciences, Inc., a ... on the Company,s lead investigational immuno-oncology drug AM0010 (PEGylated ... the American Society of Clinical Oncology (ASCO), taking place ... "AM0010 induces the expansion ... T cells in the blood and tumors of ...
(Date:1/21/2017)... 2017  Faruqi & Faruqi, LLP, a leading national securities ... "Company") (NASDAQ: KMPH ) of the federal securities ... and directors and underwriters of the Company,s April 16, 2015 ... lead plaintiff. The lawsuit has been filed in ... Johnson County on behalf of all those ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
(Date:1/20/2017)... ... 20, 2017 , ... “Christmas in Suffolk”: a story of love, secrets, ... lives in Lafayette, Indiana where she works in a daycare and looks for inspiration ... Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure of love ...
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
Breaking Medicine News(10 mins):